Nuvalent is a precision oncology biopharmaceutical company that designs and develops innovative, targeted small-molecule kinase inhibitors for patients with cancer. Utilizing advanced structure-based drug design expertise, the company engineers next-generation therapies specifically aimed at overcoming prominent clinical challenges in oncology, such as treatment resistance, acquired mutations, and poor central nervous system penetration, particularly within non-small cell lung cancer and other genomic driver-defined tumors.